About

Harsher Singh was appointed CEO of Jubilant Radiopharma in April 2024. With a proven track record in the biopharmaceutical industry, Harsher brings valuable expertise to the radiopharmaceutical division. Prior to joining the Jubilant team, Harsher was Senior Vice President at Amneal Biosciences where he led the Biosimilar, Biologic and Injectable business lines and served as Amneal's strategic leader for AvKare Distribution Business. Prior to Amneal, he worked for American Regent, Inc. and McKinsey & Company. Harsher holds an MBA from Northwestern University – Kellogg School of Management, and a BSc in Economics from the London School of Economics and Political Science.

Appointed Senior Vice President and Chief Medical Officer of Jubilant Radiopharma and Jubilant Threapeutics in 2024, bringing over 32 years of experience in medicine, cardiology, research, imaging and innovation in academic and pharmaceutical medicine to global healthcare.

Previously, Melda was Global Medical and Regulatory Affairs Executive Senior Director at Bracco Diagnostics and Research Professor at Saint Louis University Hospital Cardiology. She served as a key opinion leader in healthcare globally.

Michelle Brien, Senior Director of Human Resources at Jubilant Radiopharma, brings extensive HR executive experience from leading pharmaceuticals such as Novartis, AstraZeneca, Charles River Laboratories and currently Jubilant Radiopharma. Michelle focuses on building talent bench strength, fostering people-centric organizations, transforming HR delivery models, and securing government subsidies to support business plans. Her leadership has significantly improved employee retention and engagement. From 2019 to 2023, Michelle co-chaired the Pharmabio Board of Directors sectoral workforce committee, representing Quebec’s pharmaceutical and biotechnology sector.

Julien Troin is a seasoned pharmaceutical manufacturing leader with extensive experience in vaccine and radiopharmaceutical production. he has played a pivotal role in overseeing complex operations, ensuring compliance with stringent regulatory standards, and driving process improvements. Julien's expertise encompasses production execution quality assurance, operational excellence, and team leadership, contributing significantly to the company's mission of delivering high-quality healthcare solutions. His commitment to innovation and efficiency has been instrumental in enhancing production capabilities and maintaining the highest standards of safety and quality in the industry.

Oscar Cordeiro is a seasoned pharmaceutical quality leader with over two decades of experience in sterile manufacturing environments. Currently serving as Senior Director of Quality Operations at Jubilant Radiopharma, he oversees laboratories, quality assurance, and compliance functions, ensuring adherence to stringent regulatory standards in radiopharmaceuticals production.

Throughout his career, Oscar has demonstrated a commitment to operational excellence and team development. He actively shares insights on leadership and quality culture, emphasizing the importance of trust and autonomy in effective management.

Oscar holds a master’s in microbiology from the Université de Montréal and a DESG from HEC Montréal.

Gagan Tuteja was appointed Head of Corporate Development at Jubilant Radiopharma in November 2024. He leads the company’s strategic growth initiatives including mergers and acquisitions, in-licensing, strategic partnerships, and business development across the Radiopharmaceutical and Radiopharmacies division.

Prior to this role, Gagan served as Head of Finance for Jubilant’s Radiopharmacies Division, where he was instrumental in transforming the business. With over 15 years of experience in corporate finance, FP&A, strategy execution, business partnering and capital markets, Gagan has played a key role in multiple fundraises, acquisition & post-merger integrations, and enterprise-wide transformations.

Before joining Jubilant, Gagan worked with Ernst & Young in Transaction Advisory Services, where he led financial due diligence for strategic deals across healthcare, power, and consumer sectors. Gagan is a Qualified Chartered Accountant and holds an Executive MBA from Northwestern University’s Kellogg School of Management.

Krishna Khaitan is a seasoned finance leader with over 30 years of global experience in the pharmaceutical and manufacturing industries. As head of Finance at Jubilant Radiopharma, Krishna leads the company’s financial strategy, planning, and performance initiatives, driving operational excellence and long-term value creation.

Before joining Jubilant in 2022, Krishna served as Chief Financial Officer at AV Group, where he played a pivotal role in improving financial profitability and supporting strategic growth. He is a Chartered Accountant and holds both an MBA and a Bachelor of Commerce degree.

Krishna is widely recognized for his empathetic leadership style and commitment to human-centric management, fostering trust and collaboration across teams. His deep expertise in financial management and business transformation continues to shape Jubilant Radiopharma’s success in a dynamic healthcare landscape.